CPCorey M. Porter

Corey M. Porter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Corey M. Porter has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Karen Sandell Sfanos

    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

    2 shared publications
  • Matthias C. Truttmann

    University of Michigan

    2 shared publications
  • Anandita Rajpurohit

    The Lieber Institute for Brain Development, Baltimore, MD, 21205, USA

    1 shared publication
  • Andrew William Truman

    Department of Biological Sciences, The University of North Carolina at Charlotte, Charlotte, NC 28223, USA

    1 shared publication
  • Angelina Bilate

    Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA

    1 shared publication
  • Angelo M. De Marzo

    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

    1 shared publication

Latest Publications

  • Open Access

    Deletion of mFICD AMPylase alters cytokine secretion and affects visual short-term learning in vivo

    by Nicholas McCaul, Corey M. Porter, Anouk Becker, Chih-Hang Anthony Tang, Charlotte Wijne, Bhaskar Chatterjee, Djenet Bousbaine, Angelina Bilate, Chih-Chi Andrew Hu, Hidde Ploegh, et al.


  • Open Access

    Post-translational modifications of Hsp70 family proteins: Expanding the chaperone code

    by Nitika, Corey M. Porter, Andrew W. Truman, Matthias C. Truttmann


  • Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis

    by Corey M. Porter, Michael C. Haffner, Ibrahim Kulac, Janielle P. Maynard, Javier A. Baena-Del Valle, William B. Isaacs, Srinivasan Yegnasubramanian, Angelo M. De Marzo, Karen S. Sfanos


  • Open Access

    xMD-miRNA-seq to generate near in vivo miRNA expression estimates in colon epithelial cells

    by Avi Z. Rosenberg, Carrie Wright, Karen Fox-Talbot, Anandita Rajpurohit, Courtney Williams, Corey Porter, Olga Kovbasnjuk, Matthew N. McCall, Joo Heon Shin, Marc K. Halushka

    Accurate, RNA-seq based, microRNA (miRNA) expression estimates from primary cells have recently been described. However, this in vitro data is mainly obtained from cell culture, which is known to alter cell maturity/differentiation status, significantly changing miRNA levels. What is needed is a robust method to obtain in vivo miRNA expression values directly from cells. We introduce expression microdissection miRNA small RNA sequencing (xMD-miRNA-seq), a method to isolate cells directly from formalin fixed paraffin-embedded (FFPE) tissues. xMD-miRNA-seq is a low-cost, high-throughput, immunohistochemistry-based method to capture any cell type of interest. As a proof-of-concept, we isolated colon epithelial cells from two specimens and performed low-input small RNA-seq. We generated up to 600,000 miRNA reads from the samples. Isolated epithelial cells, had abundant epithelial-enriched miRNA expression (miR-192; miR-194; miR-200b; miR-200c; miR-215; miR-375) and overall similar miRNA expression patterns to other epithelial cell populations (colonic enteroids and flow-isolated colon epithelium). xMD-derived epithelial cells were generally not contaminated by other adjacent cells of the colon as noted by t-SNE analysis. xMD-miRNA-seq allows for simple, economical, and efficient identification of cell-specific miRNA expression estimates. Further development will enhance rapid identification of cell-specific miRNA expression estimates in health and disease for nearly any cell type using archival FFPE material.


  • The microbiome in prostate inflammation and prostate cancer

    by Corey M. Porter, Eva Shrestha, Lauren B. Peiffer, Karen S. Sfanos

    The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of the urinary microbiome in relation to prostate cancer. Less well understood are indirect interactions of the microbiome with prostate cancer, such as the influence of the gastrointestinal or oral microbiota on pro- or anti-carcinogenic xenobiotic metabolism, and treatment response. We review the literature to date on direct and indirect interactions of the microbiome with prostate inflammation and prostate cancer. Emerging studies indicate that the microbiome can influence prostate inflammation in relation to benign prostate conditions such as prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia, as well as in prostate cancer. We provide evidence that the human microbiome present at multiple anatomic sites (urinary tract, gastrointestinal tract, oral cavity, etc.) may play an important role in prostate health and disease. In health, the microbiome encourages homeostasis and helps educate the immune system. In dysbiosis, a systemic inflammatory state may be induced, predisposing remote anatomical sites to disease, including cancer. The microbiome’s ability to affect systemic hormone levels may also be important, particularly in a disease such as prostate cancer that is dually affected by estrogen and androgen levels. Due to the complexity of the potential interconnectedness between prostate cancer and the microbiome, it is vital to further explore and understand the relationships that are involved.


  • Open Access

    The parasite Toxoplasma sequesters diverse Rab host vesicles within an intravacuolar network

    by Julia D. Romano, Sabrina J. Nolan, Corey Porter, Karen Ehrenman, Eric J. Hartman, Ru-Ching Hsia, Isabelle Coppens

    Many intracellular pathogens subvert host membrane trafficking pathways to promote their replication. Toxoplasma multiplies in a membrane-bound parasitophorous vacuole (PV) that interacts with mammalian host organelles and intercepts Golgi Rab vesicles to acquire sphingolipids. The mechanisms of host vesicle internalization and processing within the PV remain undefined. We demonstrate that Toxoplasma sequesters a broad range of Rab vesicles into the PV. Correlative light and electron microscopy analysis of infected cells illustrates that intravacuolar Rab1A vesicles are surrounded by the PV membrane, suggesting a phagocytic-like process for vesicle engulfment. Rab11A vesicles concentrate to an intravacuolar network (IVN), but this is reduced in Δgra2 and Δgra2Δgra6 parasites, suggesting that tubules stabilized by the TgGRA2 and TgGRA6 proteins secreted by the parasite within the PV contribute to host vesicle sequestration. Overexpression of a phospholipase TgLCAT, which is localized to the IVN, results in a decrease in the number of intravacuolar GFP-Rab11A vesicles, suggesting that TgLCAT controls lipolytic degradation of Rab vesicles for cargo release.